• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

RCT Results: Can Controlling Fatty Acid Intake Through Diet Help Reduce Migraines?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • n-3 and n-6 fatty acids (obtained through diet) are implicated in migraine pathogenesis
    • n-6 fatty acid derivatives (oxylipins) have pain-promoting properties, while n-3 fatty acid derivatives have pain-reducing properties
    • Previous pilot studies suggest reducing n-6 fatty acid intake, while increasing n-3 fatty acids, may result in fewer headache days per month
  • Ramsden et al. (BMJ, 2021) assessed whether fatty acid dietary interventions decrease headache in adults with migraine

METHODS:

  • Three arm, parallel group, randomized, modified double blind, controlled trial
  • Participants
    • Individuals with migraines 5 to 20 days per month
    • With or without aura
    • Minimum 2 years
  • Interventions
    • H3 diet
      • Increase n-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to 1.5 g/day and maintain n-6 linoleic acid at around 7% of energy
    • H3-L6 diet
      • Increase n-3 EPA+DHA to 1.5 g/day and decrease n-6 linoleic acid to ≤1.8% of energy
    • Control diet
      • Maintain n-3 EPA+DHA at <150 mg/day and n-6 linoleic acid at around 7% of energy
  • Study design
    • All participants received foods accounting for two-thirds of daily food energy | Otherwise, continued usual care
    • Headache frequencies were assessed daily with an electronic diary
    • Diets detailed in supplementary material in the study
      • N-3 increased using high fat fish diet
      • N-6 controls given blend of corn oil and extra virgin olive oil and a blend of butter and corn oil | N-6 linoleic acid reduced diet consisted of a blend of macadamia nut oil and extra virgin olive oil and regular butter
    • Analysis was by intention to treat
  • Primary outcome (at 16 weeks)
    • Antinociceptive mediator 17-hydroxydocosahexaenoic acid (17-HDHA) blood levels
    • Headache impact test (HIT-6) | 6 item questionnaire assessing headache impact on quality of life

RESULTS:

  • H3: 61 participants | H3-L6: 61 participants | control: 60 participants
    • 88% women; mean age 38 years
    • Criteria met for chronic migraine: 67% of participants
  • The H3-L6 and H3 diets increased circulating 17-HDHA (log ng/mL) compared to the control diet
    • H3-L6: baseline-adjusted mean difference 0.6 (95% CI, 0.2 to 0.9)
    • H3: baseline-adjusted mean difference 0.7 (95% CI, 0.4 to 1.1)
  • There was an improvement in HIT-6 scores in the H3-L6 and H3 groups, but this was not statistically significant
    • H3-L6: baseline-adjusted MD −1.6 (95% CI, −4.2 to 1.0)
    • H3: baseline-adjusted MD −1.5 (95% CI, −4.2 to 1.2)
  • Compared with the control diet, the H3-L6 and H3 diets decreased
    • Total headache hours per day
      • H3-L6: baseline-adjusted MD −1.7 (95% CI, −2.5 to −0.9)
      • H3: baseline-adjusted MD −1.3 (95% CI, −2.1 to −0.5)
    • Moderate to severe headache hours per day
      • H3-L6: baseline-adjusted MD −0.8 (95% CI, −1.2 to −0.4)
      • H3: baseline-adjusted MD −0.7 (95% CI, −1.1 to −0.3)
    • Headache days per month
      • H3-L6: baseline-adjusted MD −4.0 (95% CI, −5.2 to −2.7)
      • H3: baseline-adjusted MD −2.0 (95% CI, −3.3 to −0.7)
  • The H3-L6 diet decreased headache days per month more than the H3 diet
    • Baseline-adjusted MD −2.0 (95% CI, −3.2 to −0.8)

Nociceptive Markers

  • The H3-L6 and H3 diets altered n-3 and n-6 fatty acids and several of their nociceptive oxylipin derivatives in plasma, serum, erythrocytes or immune cells
  • H3-L6 and H3 diets did not alter classic headache mediators calcitonin gene related peptide and prostaglandin E2

CONCLUSION:

  • High omega 3 and low omega 6 fatty acid diet ( linoleic acid) decreased the number of migraine headache hours per day and the number of headache days per month
    • However, patient-reported quality of life was not improved
  • An editorial provides a more optimistic viewpoint and states

International Headache Society guidelines and regulatory standards specify the use of headache or migraine frequency as the preferred outcome measure for trials of preventive interventions for migraine

Interpretation of this study’s findings is therefore complex: the study was negative according to the prespecified primary outcome, but would have been positive if judged by more guideline adherent endpoints

These results support recommending a high omega 3 diet to patients in clinical practice 

Learn More – Primary Sources:

Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial

Editorial: Dietary omega 3 fatty acids for migraine

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Migraine Treatment and Prevention
Is It a Migraine? Risk Factors and Diagnostic Categories
Cochrane Review: What is the Evidence for the Prevention of Migraines Using Botulinum toxins?
What are the Consequences of Taking Triptan for Migraine During Pregnancy?
Does Acupuncture Decrease Incidence of Migraines?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site